Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05931393
Title Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Texas Southwestern Medical Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.